Actively Recruiting

Age: 13Years - 99Years
All Genders
Healthy Volunteers
NCT00001539

A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations

Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2026-05-01

700

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

This study will determine whether patients who have been infected with the Lyme bacteria, Borrelia burgdorferi, and treated with antibiotics still have the bacteria alive inside them and whether it is causing their symptoms. The information from this study may serve as a basis for developing stringent diagnostic criteria for Lyme disease and the establishment of future treatment trials. Individuals in the following categories may be eligible for this study: chronic Lyme disease; chronic Lyme arthritis; seropositive control (are infected with the bacteria that causes Lyme disease but do not have disease symptoms); recovered control (have been sick with Lyme disease but were treated successfully and are currently well); control with multiple sclerosis (patients with multiple sclerosis); and healthy volunteers. Patients in the chronic Lyme disease category must be age 13 and above; all others must be age18 and above. Candidates will be screened with blood and urine tests. Participants will have a physical examination and the following tests: Blood tests Includes HLA-typing, a genetic test of immune system markers; Leukapheresis Collection of large numbers of white blood cells Whole blood is collected through a needle in an arm vein. The blood circulates through a machine that separates it into its components. The white cells are removed and the rest of the blood is returned to the body, either through the same needle used to draw the blood or through another needle in the other arm. (Alternatively, patients will 100 cc (about 7 tablespoons) of blood drawn.); Lumbar puncture (spinal tap) Collection of cerebrospinal fluid (CSF, fluid that bathes the brain and spinal cord). A local anesthetic is administered and a needle is inserted in the space between the bones in the lower back where the cerebrospinal fluid circulates below the spinal cord. A small amount of fluid is collected through the needle; Magnetic resonance imaging (MRI) of the brain Imaging of the brain using a strong magnetic field and radio waves instead of X-rays. During the scan, the patient lies on a table in a narrow cylinder containing a magnetic field. He or she can speak with a staff member via an intercom at all times during the procedure; Neuropsychologic testing; Some participants may also have a hearing test and urine collection. Participants whose test results are positive for Borrelia burgdorferi will be followed at NIH at intervals of 3 to 6 months until it is determined whether there is infection. Those who are infected will be offered treatment with the antibiotic ceftriaxone. Following treatment, patients will return to the NIH Clinical Center for follow-up visits 1 week after treatment and again at 3, 6 and 12 months. The lumbar puncture, hearing examination, blood and urine tests will be repeated at these visits to evaluate the response to treatment, and the leukapheresis will be repeated for research purposes. Patients whose MRI was abnormal during therapy will have a repeat MRI at the 3-month, 6-month and 1-year visits. All participants with chronic Lyme disease, chronic Lyme arthritis, seropositive controls and recovered controls may be reevaluated at intervals of 6 to 12 months.

CONDITIONS

Official Title

A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations

Who Can Participate

Age: 13Years - 99Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 13 years or older for suspected post-treatment Lyme disease syndrome
  • Age 18 years or older for chronic Lyme arthritis, seropositive controls, recovered controls, multiple sclerosis controls, and healthy volunteers
  • Diagnosis of confirmed or probable Lyme disease according to CDC definition for PTLDS group
  • Received recommended antibiotic therapy for Lyme disease
  • Persistent or relapsing symptoms or signs for at least six months after antibiotic therapy for PTLDS group
  • No other documented explanation for symptoms in PTLDS group
  • Positive serum antibodies to Borrelia burgdorferi for Lyme arthritis controls
  • Recovered controls must have completed antibiotic treatment at least 3 months prior and be currently symptom-free
  • Seropositive controls must have positive serum IgG antibody response but no symptoms and no antibiotic treatment history
  • OspA vaccinated controls must have received at least two doses of OspA vaccine for Lyme disease
  • Multiple sclerosis controls must have diagnosis of relapsing-remitting or progressive multiple sclerosis and no evidence of Lyme exposure
  • Healthy volunteers must have no history or serological evidence of Lyme disease
Not Eligible

You will not qualify if you...

  • Age under 13 for PTLDS group and under 18 for all other groups
  • Weight less than 70 pounds (35 kg)
  • Pregnant or lactating women
  • Women of childbearing potential not using effective contraception during study phases
  • Significant laboratory abnormalities including positive tests for syphilis, hepatitis B, hepatitis C, or HIV
  • Chronic medication use evaluated case-by-case
  • Inability to understand study requirements or provide informed consent
  • Refusal to allow use of samples for future research
  • Use of immunosuppressive drugs or immunomodulators
  • History of autoimmune diseases such as rheumatoid arthritis or lupus
  • Serious chronic medical or psychiatric illnesses other than Lyme disease
  • Significant head trauma, substance abuse, or other neurological conditions
  • Use of systemic antibiotics in the previous month
  • Significant impairment in judgment or reasoning affecting decision-making
  • For recovered, seropositive, vaccinated, and healthy controls: any serious chronic medical or psychiatric illness
  • For multiple sclerosis controls: treatments like total lymphoid irradiation or cladribine, recent immunoactive drugs (except beta-interferon), or investigational treatments within 3 months before study start
  • Adults lacking capacity to consent or who lose this ability during study participation
  • NIH staff participation will not affect employment status and information confidentiality is protected

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

National Institutes of Health Clinical Center

Bethesda, Maryland, United States, 20892

Actively Recruiting

Loading map...

Research Team

A

Ashley M Thomas

CONTACT

A

Adriana R Marques, M.D.

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

8

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here